Zelic: Those who received 2 doses are not among Covid victims. Way out of epidemic by late June?
Pavle Zelic from the Medicines and Medical Devices Agency of Serbia (ALIMS) said today that 736 adverse reactions to all vaccines against coronavirus have been recorded so far.
The vaccine is effective, safe and we can see a way out (of the epidemic), Zelic told RTS and stressed that there aren't any people who received both dosese among those who died from Covid.
"Studies from the US, Israel, the UK show that, it will be shown in our country as well that the vaccines work and produce an effect, and this will end at some point. In America, they said by July 4, I would say perhaps by our biggest holiday, Vidovdan, June 28, we could find a final way out of this epidemic," Zelic added.
Zelic also said that by Monday at noon, a total of 736 adverse reactions to all vaccines administered in Serbia had been recorded, the majority concerning the Sinopharm vaccine - 263.
"We're checking it all. When we look at the total number of those who have gotten vaccinated, it's negligible," Zelic stressed.
He stated that there were a total of five severe reactions, but that none of them required prolonged hospitalization.
When it comes to combating the influence of anti-vaxxers and fake news, Zelic said that ALIMS has been dealing with social networks in the past few weeks in order to debunk false information.
"We must be constantly vigilant in reacting to such phenomena. We are also active through outreach, we must talk to people, explain to them, encourage them, it's enough to get information through personal contact," said Zelic.
He pointed out that the essence is to strengthen trust in institutions.
Zelic said that citizens can call him on 011 3951 139 to chat and get all the necessary information about the studies and the ingredients of the vaccines.
(Telegraf.rs)
Video: Ovo je kuća u kojoj je uhapšen Alija Balijagić
Telegraf.rs zadržava sva prava nad sadržajem. Za preuzimanje sadržaja pogledajte uputstva na stranici Uslovi korišćenja.